SGLT2 inhibitor therapy leads to a small but significant increase in hemoglobin level in patients with diabetes, including those with moderate to severe CKD.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: